The LORIS Trial: Addressing Overtreatment of Ductal Carcinoma In Situ-Reference-Cited by-同舟云学术

The LORIS Trial: Addressing Overtreatment of Ductal Carcinoma In Situ

Published:2015-01 Issue:1 Volume:27 Page:6-8
ISSN:0936-6555
Container-title:Clinical Oncology
language:en
Short-container-title:Clinical Oncology

Author:

Francis A.,Fallowfield L.^ORCID,Rea D.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference21 articles.

1. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality?;Jorgensen;Radiology,2011

2. Mammographic screening and “overdiagnosis”;Kopans;Radiology,2011

3. http://www.cancerresearchuk.org/cancer/info/cancerstats/types/breast/Incidence-in-situ/.

4. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/ [accessed 05.01.14].

5. An audit of screen detected breast cancers for the year of screening April 2012 to March 2013 PHE;NHS Breast Screening Programme and Association of Breast Surgery,2014

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imaging Changes and Outcomes of Patients Undergoing Active Monitoring for Ductal Carcinoma In Situ: Seven-Year Follow-up Study;Academic Radiology;2024-07

2. Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study;BMJ;2024-01-24

3. Radiology for Ductal Carcinoma In Situ of the Breast: Updates on Invasive Cancer Progression and Active Monitoring;Korean Journal of Radiology;2024

4. Evolving Treatment Paradigms for Low-Risk Ductal Carcinoma In Situ: Imaging Needs;American Journal of Roentgenology;2023-12-13

5. Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study;BMJ;2023-10-30